“Transdermal Solutions Encompassing The Company’s Researched Delivery Matrix”
Nauseasol Skin Renou HA Kenestrin Gel Viorra (TM) XILIVE FSAD Drug
Applied anywhere any where increased absorption in the blood stream occurs. 1 hour – 30 min prior to traveling. Odorless and colorless
Anti-aging wrinkle cream using hyaluronic acid. Hyaluronic Acid occurs in the deeper layers of our skin known as the dermis and it appears to help keep the skin smooth because of it’s water retention qualities.
Hyaluronic Acid also apparently helps to repair skin wounds and certain other problems. In addition, it appears to help maintain collagen levels.
Under normal circumstances, collagen depletion is widely considered to be a prime factor in subpar skin tone as well as elasticity of the skin, something that is often associated with the visual aging process.
For arthritis, knees, elbows, shoulders, wrist, back pain. Great for those that are waiting on surgeries (i.e. knees).
Apply every 4 hours for the first 2-3 days – Relief lasts over a week – Odorless and colorless
Viorra is an all-natural, hormone free, non-toxic, topical gel that is endorsed by some of the world’s leading medical experts on women’s sexuality.
The doctor recommended daily use of ViorraTM Sensuality Solution helps to restore and improve moisture and vaginal elasticity, improving sexual functioning for women.
The improvement of sexual functioning of women has a positive effect on sexual desire, arousal and the ability to experience orgasms.
More…
Early stage cancer drug with impressive long-term anecdotal results in several patients with intractable late-stage cancer.
Easton intends to pursue controlled clinical trial development of XILIVE and may seek fast-track or orphan drug status.
Easton will also invest in a patent strategy reflecting the unique characteristics of this drug.
Patented and or Patent Pending Drug designed to treat FSAD
Drug Delivery Technology
In October of 2013, the company purchased 50% ownership of a drug to treat FSAD (Female Sexual Arousal Disorder). The drugs transdermal delivery technology is a safe, novel and proprietary drug delivery platform that has been developed based on years of research by various individuals to address many of the needs in the multi billion dollar drug delivery segment of the pharmaceutical market.
The proprietary system used only in Femlife consists of a water based, complex polymer matrix, which includes methoxypolyethyleneglycol, hydroxyethylcellulose and carboxymethylcellulose. The FSAD Drug in 2008 underwent a clinical trial at Cedar Sinai Medical Center in Beverley Hills, CA. which was prematurely ended, but not known to be as a result of lack of efficacy but due to other reasons.
Included with the 50% ownership interest with the purchase of the FSAD Drug are the following patents or patent pendings:
(i) Canadian Patent Application Number CA 2.591.203;
(ii) U.S. Patent Application No. 11/010,154;
Patent Cooperation Treaty Application Number PCT/IB2005/003672 (publication number W02006/061689; and
(iii) European Patent Application Number EP 2005810583
XILIVE Cancer Drug
On November 5, 2013 EASTON PHARMACEUTICALS, Inc. acquired an initial 10% ownership interest in a Cancer Treatment Drug called “XILIVE”, with an exclusive option to purchase the remaining ownership interest exercisable at any point in time over the next 12 month time period. Should EASTON PHARMACEUTICALS provide funding towards any testing or clinical trials, these expenditures will be included and put towards acquiring an additional ownership in the drug.
“XILIVE” has not undergone any independent clinical trials, but was previously administered by the current majority owners on 2 individuals suffering from various forms of advanced stage cancer. Initial feedback was promising enough to allow EASTON PHARMACEUTICALS to acquire an initial 10% ownership interest. It is the Companys Intent along with the current majority owners to enter into some type of feasilbilty, safety and efficacy tests.
Any type of trials may depend on the involvement or the approval of the FDA in the United States and Health Canada in Canada. The Company is currently contemplating forming alliances with certain other company’s who have adequate resources and knowledge towards such trials in the jurisdiction of the United States and Canada. Other avenues being seriously contemplated are to have “XILIVE” utilized and tested in various other countries such as Mexico, Germany, Italy and other countries where regulations are less stringent for the use of experimental early stage drugs for the treatment of certain cancers.
Drop files to upload Drop files to upload Drop files to upload Drop files to upload Drop files to upload
Female Sexual Arousal Dysfunction
EASTON PHARMACEUTICALS, Inc. (formerly LAM) first product, Viorra for women is the first product using EASTON PHARMACEUTICALS, Inc. (formerly LAM) priority VDM technology and is designed primarily to address the deficiencies in women experiencing FASD, which is often associated with post-menopausal problems that may inhibit their intimate relationships. Specifically, Viorra, using VDM technology acts to either eliminate or significantly minimize post-menopausal symptoms including vaginal dryness, pain during intercourse, while improving feeling and sensation.
Drug Delivery Technology
In October of 2013, the company purchased 50% ownership of a drug to treat FSAD (Female Sexual Arousal Disorder). The drugs transdermal delivery technology is a safe, novel and proprietary drug delivery platform that has been developed based on years of research by various individuals to address many of the needs in the multi billion dollar drug delivery segment of the pharmaceutical market. The proprietary system used only in Femlife consists of a water based, complex polymer matrix, which includes methoxypolyethyleneglycol, hydroxyethylcellulose and carboxymethylcellulose. The FSAD Drug in 2008 underwent a clinical trial at Cedar Sinai Medical Center in Beverley Hills, CA. which was prematurely ended, but not known to be as a result of lack of efficacy but due to other reasons.
Included with the 50% ownership interest with the purchase of the FSAD Drug are the following patents or patent pendings:
(i) Canadian Patent Application Number CA 2.591.203;
(ii) U.S. Patent Application No. 11/010,154;
Patent Cooperation Treaty Application Number PCT/IB2005/003672 (publication number W02006/061689; and
(iii) European Patent Application Number EP 2005810583
Drop files to upload Drop files to upload Drop files to upload Drop files to upload Drop files to upload